On October 9, Jazz Pharmaceuticals PLC fell 6.43% in regular trading, trading at $215.56/share, with Turnover of $1.22 billion.

The decline came after the company planned to file a label supplement with the FDA to withdraw the second-line indication for Zepzelca in small cell lung cancer, while keeping the first-line maintenance indication unchanged. The phase 3 Lagoon trial for that setting had already failed to meet its overall survival primary endpoint in June, so the withdrawal itself was expected, but it still intensified near-term concerns over the oncology pipeline.

Broader sector weakness added pressure: within the pharmacy sector, Eli Lilly fell 4.21%, Johnson & Johnson fell 2.22%, and Pfizer fell 1.84%, while Pacira Pharmaceuticals rose 43.95% and Veradermics rose 15.45%.

Jazz Pharmaceuticals identifies, develops, and commercializes pharmaceutical products for unmet medical needs, including Xywav, Xyrem, Epidiolex, Zepzelca, Rylaze, and Defitelio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)